TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation
Description: Bilateral pulmonary vein isolation using radiofrequency energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter pulmonary vein isolation without additional lesions
Description: Bilateral pulmonary vein isolation using radiofrequency energy
Study: NCT03836599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants will receive allopurinol 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants will receive allopurinol 300 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
Study: NCT03116360

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Ultrasound
Description: The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
Study: NCT00002946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penclomedine
Study: NCT03659539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROPOFOL
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
Study: NCT02202187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: Investigational Study Drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03034434

Intervention type: DEVICE
Intervention: Trans-vaginal ultrasound
Description: Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
Study: NCT00955721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
Study: NCT01250431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: 10 EFT sessions
Study: NCT01792648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard reference diet
Description: 50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond supplemented diet
Description: 50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate reference diet
Description: 26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
Study: NCT03782558

Intervention type: PROCEDURE
Intervention: Surgical transection of transverse ligament
Description: Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
Study: NCT02375516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Program
Description: Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
Study: NCT05019781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Description: Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tape
Description: The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
Study: NCT03103412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-3504
Description: TD-3504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-3504
Description: TD-3504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-3504
Description: TD-3504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N2-tofacitinib
Description: 15N2-tofacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N2-tofacitinib
Description: 15N2-tofacitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N2-tofacitinib
Description: 15N2-tofacitinib
Study: NCT00955721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
Study: NCT04344405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D supplementation
Study: NCT01447784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune HDM
Description: Intradermal injection 1 x 11 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 11 administrations 4 weeks apart
Study: NCT02692027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Description: Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis.
Study: NCT00460213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg daily
Study: NCT04580550

Intervention type: OTHER
Group type: OTHER
Intervention: Axial length variability
Description: Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
Study: NCT03018873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning （RIPC）
Description: once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning （RIPC）
Description: once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study: NCT03254784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Capsule
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet
Study: NCT04521374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein
Description: Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
Study: NCT03254784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Oral tablet
Study: NCT03466151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study: NCT04521374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein
Description: Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein
Description: Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
Study: NCT03466151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study: NCT03014258

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NF54 P. falciparum malaria challenge
Description: Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
Study: NCT00982280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period.
Study: NCT01121757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
Study: NCT03773484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid naive
Description: Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-risk for long term use
Description: Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term opioid recipient
Description: Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
Study: NCT00928772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM
Description: APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY
Description: CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED
Description: NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
Study: NCT02985723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA tri toric 939MP
Study: NCT05032586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing virtual reality headsets
Description: When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale.
Study: NCT02239237

Intervention type: DRUG
Intervention: Compound Kuh-seng Injection
Description: Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
Study: NCT00408629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo for prefilled syringe, 40 mg,
Study: NCT00547573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth as needed for 12 weeks not more than once a day
Study: NCT00282100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefetinib (Iressa)
Study: NCT03878589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin (OT)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin (OT)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
Study: NCT03854474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV